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26, 2013.ReplyManagement of Tricuspid Regurgitation
by Caval Valve Implantation
From Technical Feasibility to
Evaluation of Efﬁcacy
We appreciate the comments by Dr. Lauten and colleagues on
our caval vein approacheswith theEdwards SapienXTvalve (Edwards
Lifesciences, Irvine, California) to treat severe secondary tricuspid
regurgitation (STR) (1), and we welcome the opportunity to reply to
their letter. Since the publication of our letter, we have performed 4
additional procedures, with the result that our experience now includes
7 patients, with follow-ups ranging between 1 and 14 months.
We agree that caval valve implantation (CAVI) is restricted to
STR. Relevant regurgitation into hepatic and caval veins can easily
be veriﬁed by clinical examination and ultrasound Doppler ﬂow
proﬁles. Indeed, although CAVI does not affect tricuspid regurgi-
tation, the allegedly compromising heterotopic inferior vena cava
(IVC) single-vein approach offers a number of important advan-
tages over complete valve replacement in anatomic valve position.
First, provided that CAVI primarily represents a tool in advancedheart failure, frequently under conditions of impaired right ventricular
(RV) function and pulmonary hypertension (PH), the IVC single-
valve approach provides a safety valve by leaving the superior vena
cava untreated. Also, the majority of patients with heart failure
have transvalvular RV-pacemaker and/or implantable cardioverter-
deﬁbrillator leads, a fact that renders catheter-based valve replace-
ment in anatomic position virtually impossible. In heterotopic IVC
position, however, the leads do not interfere in any way.
The stipulations voiced by Dr. Lauten and colleagues to apply
CAVI only under a condition of normal RV function and
pulmonary vascular resistance are based on an absolutely valid,
established safety approach. At the same time, one can hardly ﬁnd
a patient with this constellation in advanced stages of heart failure.
Our experience, which is admittedly limited, has shown, conversely,
that CAVI can very well be conducted with pathological right-
heart and pulmonary hemodynamics. Indeed, 5 of our 6 patients
exhibited PH (and 2 with systolic pulmonary artery pressure
>60 mm Hg). CAVI did not further increase pulmonary artery
pressure and was well tolerated. Five of the 6 patients suffered from
impaired RV systolic function. In all patients, tricuspid annular
plane systolic excursion signiﬁcantly increased (from a mean of
14.5 mm to 18.6 mm), which indicates partial reversibility of
longitudinal systolic RV function.
Finally, Dr. Lauten and colleagues are correct in stating that in
STR, the FCI diameter is actually too large for the available valve
types. In our patients, the diameters were between 28 and 33 mm,
which meant that direct valve implantation was not possible,
primarily for this reason. Therefore, we prepared a landing zone, with
2 stents implanted 1 over the other. This method enables successful
stabilization and downsizing, and implantation of the 29-mm
Edwards Sapien XT becomes possible. Approximately 10% of the
screened patients had larger diameters (>35 mm) and were not able
to be treated. The occurrence of large vein diameters should actually
prompt design of an appreciably larger dedicated valve.
Dr. Lauten and colleagues request further echo and pressure
parameters to support our concept. The space limitation involved
here in this Reply prevented their presentation; these data will be
included in a publication of ours to appear later.*Michael Laule, MD
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